Literature DB >> 7862122

The human leukemia oncogene bcr-abl abrogates the anchorage requirement but not the growth factor requirement for proliferation.

M W Renshaw1, J R McWhirter, J Y Wang.   

Abstract

Proliferation of normal cells in a multicellular organism requires not only growth factors but also the proper attachment to the extracellular matrix. A hallmark of neoplastic transformation is the loss of anchorage dependence which usually accompanies the loss of growth factor requirement. The Bcr-Abl tyrosine kinase of human leukemias is shown here to abrogate only the anchorage, not the growth factor, requirement. Bcr-Abl-transformed cells grow in soft agar but do not proliferate in serum-free media. Bcr-Abl does not activate the mitogenic pathway, as indicated by its inability to induce enhancers such as the serum response element or the tetradecanoyl phorbol acetate response element (TRE). However, Bcr-Abl can alleviate the anchorage requirement for the induction of the TRE enhancer; i.e., it allows serum to activate the TRE in detached cells. This activity is dependent on the association of an active Bcr-Abl tyrosine kinase with the actin filaments. Despite its association with the adapter protein Grb2, Bcr-Abl's effect on the TRE enhancer is not blocked by dominant negative Ras or Raf. The finding that Bcr-Abl tyrosine kinase abrogates only anchorage dependence may have important implications on the pathogenesis of chronic myelogenous leukemia.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7862122      PMCID: PMC230351          DOI: 10.1128/MCB.15.3.1286

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  62 in total

1.  Direct contact between human primitive hematopoietic progenitors and bone marrow stroma is not required for long-term in vitro hematopoiesis.

Authors:  C M Verfaillie
Journal:  Blood       Date:  1992-06-01       Impact factor: 22.113

2.  Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.

Authors:  G Q Daley; R A Van Etten; D Baltimore
Journal:  Science       Date:  1990-02-16       Impact factor: 47.728

3.  Signaling by integrins: implications for tumorigenesis.

Authors:  M A Schwartz
Journal:  Cancer Res       Date:  1993-04-01       Impact factor: 12.701

4.  Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane.

Authors:  S J Leevers; H F Paterson; C J Marshall
Journal:  Nature       Date:  1994-06-02       Impact factor: 49.962

5.  A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia.

Authors:  L C Chan; K K Karhi; S I Rayter; N Heisterkamp; S Eridani; R Powles; S D Lawler; J Groffen; J G Foulkes; M F Greaves; L M Wiedemann
Journal:  Nature       Date:  1987 Feb 12-18       Impact factor: 49.962

6.  Nonmyristoylated Abl proteins transform a factor-dependent hematopoietic cell line.

Authors:  G Q Daley; R A Van Etten; P K Jackson; A Bernards; D Baltimore
Journal:  Mol Cell Biol       Date:  1992-04       Impact factor: 4.272

7.  A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia.

Authors:  A de Klein; A G van Kessel; G Grosveld; C R Bartram; A Hagemeijer; D Bootsma; N K Spurr; N Heisterkamp; J Groffen; J R Stephenson
Journal:  Nature       Date:  1982-12-23       Impact factor: 49.962

8.  In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome.

Authors:  J McLaughlin; E Chianese; O N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  1987-09       Impact factor: 11.205

9.  A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins.

Authors:  J R McWhirter; D L Galasso; J Y Wang
Journal:  Mol Cell Biol       Date:  1993-12       Impact factor: 4.272

10.  Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway.

Authors:  L Puil; J Liu; G Gish; G Mbamalu; D Bowtell; P G Pelicci; R Arlinghaus; T Pawson
Journal:  EMBO J       Date:  1994-02-15       Impact factor: 11.598

View more
  22 in total

1.  The Abl-related gene (Arg) nonreceptor tyrosine kinase uses two F-actin-binding domains to bundle F-actin.

Authors:  Y Wang; A L Miller; M S Mooseker; A J Koleske
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

2.  BCR/ABL induces multiple abnormalities of cytoskeletal function.

Authors:  R Salgia; J L Li; D S Ewaniuk; W Pear; E Pisick; S A Burky; T Ernst; M Sattler; L B Chen; J D Griffin
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

3.  Cellular aging is a critical determinant of primary cell resistance to v-src transformation.

Authors:  N Tavoloni; H Inoue
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

4.  Inactivation of pRB-related proteins p130 and p107 mediated by the J domain of simian virus 40 large T antigen.

Authors:  H Stubdal; J Zalvide; K S Campbell; C Schweitzer; T M Roberts; J A DeCaprio
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

5.  Growth factor activation of MAP kinase requires cell adhesion.

Authors:  M W Renshaw; X D Ren; M A Schwartz
Journal:  EMBO J       Date:  1997-09-15       Impact factor: 11.598

6.  The carboxyl terminus of v-Abl protein can augment SH2 domain function.

Authors:  D Warren; A J Heilpern; K Berg; N Rosenberg
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

7.  Mutant forms of growth factor-binding protein-2 reverse BCR-ABL-induced transformation.

Authors:  M L Gishizky; D Cortez; A M Pendergast
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

8.  PTPROt inactivates the oncogenic fusion protein BCR/ABL and suppresses transformation of K562 cells.

Authors:  Tasneem Motiwala; Sarmila Majumder; Kalpana Ghoshal; Huban Kutay; Jharna Datta; Satavisha Roy; David M Lucas; Samson T Jacob
Journal:  J Biol Chem       Date:  2008-11-07       Impact factor: 5.157

9.  The RhoGEF domain of p210 Bcr-Abl activates RhoA and is required for transformation.

Authors:  S Sahay; N L Pannucci; G M Mahon; P L Rodriguez; N J Megjugorac; E V Kostenko; H L Ozer; I P Whitehead
Journal:  Oncogene       Date:  2007-10-08       Impact factor: 9.867

10.  The product of the cbl oncogene forms stable complexes in vivo with endogenous Crk in a tyrosine phosphorylation-dependent manner.

Authors:  V Ribon; S Hubbell; R Herrera; A R Saltiel
Journal:  Mol Cell Biol       Date:  1996-01       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.